Status:
RECRUITING
Metformin as a Neuroprotective Therapy for Glaucoma
Lead Sponsor:
Christopher Kai Shun Leung
Conditions:
Glaucoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Glaucoma, a chronic degenerative disease of the optic nerve, is the leading cause of irreversible blindness worldwide. Although lowering the intraocular pressure (IOP) has been shown to be effective t...
Detailed Description
125 POAG patients who show progressive RNFL/GCIPL thinning by TPA or GPA in at least one eye will be consecutively recruited from the HKU Eye Centre, Grantham Hospital after obtaining written informed...
Eligibility Criteria
Inclusion
- age ≥18 years
- best corrected VA ≥20/40
- IOP ≤24mmHg at the screening and baseline visits
- progressive RNFL and/or GCIPL thinning by TPA or GPA over the past 3 years in at least one eye.
Exclusion
- patients with DM, kidney or liver diseases
- pathological myopia
- cognitive impairment (e.g. Alzheimer's disease)
- diseases that may cause visual field loss or optic disc abnormalities other than glaucoma
- inability to perform reliable visual field
- suboptimal quality of OCT images.
- Both eyes of a patient will be included in the analysis if both eyesare eligible for inclusion.
Key Trial Info
Start Date :
June 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
125 Patients enrolled
Trial Details
Trial ID
NCT05426044
Start Date
June 1 2025
End Date
December 31 2027
Last Update
November 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
HKU Eye Centre
Wong Chuk Hang, Hong Kong